Published in Am J Transplant on February 01, 2004
Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell (2010) 3.33
Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol (2010) 2.69
Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev (2010) 1.68
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol (2008) 1.56
Risk of lymphoma subtypes after solid organ transplantation in the United States. Br J Cancer (2013) 1.17
Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol (2011) 1.16
Cancer in the transplant recipient. Cold Spring Harb Perspect Med (2013) 1.06
Increased risk for lymphoid and myeloid neoplasms in elderly solid-organ transplant recipients. Cancer Epidemiol Biomarkers Prev (2010) 1.03
Treating rheumatic patients with a malignancy. Arthritis Res Ther (2011) 1.03
Does the immune system naturally protect against cancer? Front Immunol (2014) 1.02
The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica (2010) 0.98
Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol (2010) 0.98
Management and prevention of post-transplant malignancies in kidney transplant recipients. Clin Kidney J (2015) 0.97
Is there truly a risk of lymphoma from biologic therapies? Dermatol Ther (2009) 0.96
Post-transplant lymphoproliferative disorder localized in the colon after liver transplantation: report of a case. Surg Today (2009) 0.95
Current concepts and perspectives of immunosuppression in organ transplantation. Langenbecks Arch Surg (2007) 0.94
Plasma cell neoplasms in US solid organ transplant recipients. Am J Transplant (2013) 0.92
Successful Treatment of Posttransplant EBV-Associated Lymphoma and Plasmacytoma Solely Localized to the CNS. Case Rep Hematol (2012) 0.91
Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients. Am J Transplant (2011) 0.91
Association of antibody induction immunosuppression with cancer after kidney transplantation. Transplantation (2015) 0.90
Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients. Transpl Infect Dis (2011) 0.89
Helminths and immunological tolerance. Transplantation (2014) 0.89
Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep (2013) 0.89
Hodgkin lymphoma among US solid organ transplant recipients. Transplantation (2010) 0.88
EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management. Exp Mol Med (2015) 0.87
Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant (2011) 0.87
Monitoring and managing viral infections in pediatric renal transplant recipients. Pediatr Nephrol (2011) 0.86
Post-transplant lymphoproliferative disease. Pediatr Nephrol (2007) 0.86
Epstein-Barr virus-associated lymphoproliferative disorder developed following autologous peripheral blood stem cell transplantation for relapsing Hodgkin's lymphoma. Oncol Lett (2012) 0.85
Donor transmitted and de novo cancer after liver transplantation. World J Gastroenterol (2014) 0.85
New directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunity. Drugs (2014) 0.84
Pediatric heart transplantation-indications and outcomes in the current era. J Thorac Dis (2014) 0.84
Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy. Drug Des Devel Ther (2014) 0.84
Post-transplantation malignancy: a cell autonomous mechanism with implications for therapy. Trans Am Clin Climatol Assoc (2009) 0.83
Posttransplant lymphoproliferative disease after pediatric solid organ transplantation. Clin Dev Immunol (2013) 0.83
Immune surveillance and lymphoid malignancy in immunocompromised host. Am J Blood Res (2013) 0.82
Surgical management of perforated gastrointestinal posttransplantation lymphoproliferative disorder after heart transplantation. Int Surg (2015) 0.82
Lymphomatoid granulomatosis treated successfully with rituximab in a renal transplant patient. J Transplant (2011) 0.82
Post-transplantation malignancies: here today, gone tomorrow? Nat Rev Clin Oncol (2015) 0.81
Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol (2015) 0.81
Orthotopic liver transplantation and what to do during follow-up: recommendations for the practitioner. Nat Clin Pract Gastroenterol Hepatol (2008) 0.81
Posttransplant lymphoproliferative disease after lung transplantation. Clin Dev Immunol (2013) 0.80
Neurological complications of solid organ transplantation. Neurohospitalist (2013) 0.80
Pediatric heart transplantation. J Thorac Dis (2015) 0.80
Risk of diffuse large B-cell lymphoma after solid organ transplantation in the United States. Am J Hematol (2014) 0.80
Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol (2010) 0.80
Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients. Virol J (2011) 0.79
Survival patterns in patients with Hodgkin's lymphoma with a pre-existing hospital discharge diagnosis of autoimmune disease. J Clin Oncol (2010) 0.79
The unintended effects of a boxed warning. J Clin Aesthet Dermatol (2009) 0.79
Global burden of deaths from Epstein-Barr virus attributable malignancies 1990-2010. Infect Agent Cancer (2014) 0.79
Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells. BMC Cancer (2006) 0.78
Malignancies after pediatric kidney transplantation: more than PTLD? Pediatr Nephrol (2013) 0.78
Impact of immunosuppression on recall immune responses to influenza vaccination in stable renal transplant recipients. Transplantation (2014) 0.78
Tumour necrosis factor gene polymorphism: a predictive factor for the development of post-transplant lymphoproliferative disease. Br J Cancer (2009) 0.78
Post-transplant lymphoproliferative disorders: role of viral infection, genetic lesions and antigen stimulation in the pathogenesis of the disease. Mediterr J Hematol Infect Dis (2009) 0.78
Immune profiling and cancer post transplantation. World J Nephrol (2015) 0.77
A case for immunosuppression for myoblast transplantation in duchenne muscular dystrophy. Mol Ther (2009) 0.77
Multiple cavitating nodules in a renal transplant recipient. Can Respir J (2009) 0.77
Post-transplantation lymphoproliferative disorder in living-donor liver transplantation: a single-center experience. Surg Today (2012) 0.77
Thymoglobulin induction in heart transplantation: patient selection and implications for maintenance immunosuppression. Transpl Int (2014) 0.76
Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget (2015) 0.76
Phase I clinical trial of valacyclovir and standard of care cyclophosphamide in children with endemic Burkitt lymphoma in Malawi. Clin Lymphoma Myeloma Leuk (2012) 0.76
Use of cyclosporine in uterine transplantation. J Transplant (2011) 0.75
Running in the family: MALT lymphoma and autoimmune disease in mother and daughter. World J Gastrointest Oncol (2012) 0.75
Treatment of post-transplantation lymphoproliferative disorders after kidney transplant with rituximab and conversion to m-TOR inhibitor. Colomb Med (Cali) (2016) 0.75
Late onset epstein barr virus seropositive posttransplant lymphoproliferative disorder in two renal transplant receivers. Turk J Haematol (2013) 0.75
HLA Associations and Risk of Posttransplant Lymphoproliferative Disorder in a Danish Population-Based Cohort. Transplant Direct (2015) 0.75
A Comparison of Two Types of Rabbit Antithymocyte Globulin Induction Therapy in Immunological High-Risk Kidney Recipients: A Prospective Randomized Control Study. PLoS One (2016) 0.75
Treatment of advanced rectal cancer after renal transplantation. World J Gastroenterol (2011) 0.75
Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management. Transplant Direct (2015) 0.75
Biologics in renal transplantation. Pediatr Nephrol (2014) 0.75
(18)F-FDG PET/CT for the Diagnosis of Malignant and Infectious Complications After Solid Organ Transplantation. Nucl Med Mol Imaging (2016) 0.75
Is there a difference in post-transplant lymphoproliferative disorder in adults after solid organ and haematologic stem cell transplantation? Experience in 41 patients. Br J Radiol (2015) 0.75
FDG-PET/CT in abdominal post-transplant lymphoproliferative disease. Br J Radiol (2015) 0.75
Posttransplantation lymphoproliferative disorder after pediatric solid organ transplantation: experiences of 20 years in a single center. Korean J Pediatr (2017) 0.75
The malignant side of successful transplantation. Am J Transplant (2004) 0.75
Posttransplant lymphoproliferative disorders following liver transplantation: Where are we now? World J Gastroenterol (2015) 0.75
Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation. Transplant Res (2016) 0.75
Epstein-Barr virus: general factors, virus-related diseases and measurement of viral load after transplant. Rev Bras Hematol Hemoter (2011) 0.75
Posttransplant lymphoproliferative disorder presenting as a small bowel obstruction in a patient with pancreas transplantation alone. Proc (Bayl Univ Med Cent) (2014) 0.75
Post-transplant lymphoproliferative disorder associated with immunosuppressive therapy for renal transplantation in rhesus macaques (Macaca mulatta). Exp Toxicol Pathol (2013) 0.75
Post cardiac transplantation T-cell lymphoproliferative disorder presenting as a solitary lung nodule. Int J Clin Exp Pathol (2013) 0.75
Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders. World J Gastrointest Pathophysiol (2015) 0.75
Posttransplantation lymphoproliferative disorder involving liver after renal transplantation. Korean J Hepatol (2011) 0.75
Post-Transplant Lymphoproliferative Disorder Presenting as CD20-Negative Plasmablastic Lymphoma in the Lung. Rare Tumors (2016) 0.75
Tissue is the issue: a solitary cerebral lesion 15 years after kidney transplantation. NDT Plus (2011) 0.75
De novo cancer in patients on dialysis and after renal transplantation: north-western Italy, 1997-2012. J Nephrol (2017) 0.75
Risk Factors and Outcomes of De novo Cancers (Excluding Nonmelanoma Skin Cancer) after Liver Transplantation for Primary Sclerosing Cholangitis. Transplantation (2017) 0.75
Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients. Exp Hematol Oncol (2017) 0.75
Monomorphic Post-transplant Lymphoproliferative Disorder After Kidney Transplantation and Hematopoietic Stem Cell Transplantation: Clinicopathological Characteristics, Treatments and Prognostic Factors. Indian J Hematol Blood Transfus (2017) 0.75
Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med (2007) 5.31
Multicenter analysis of kidney preservation. Transplantation (2007) 2.39
C3 polymorphisms and allograft outcome in renal transplantation. N Engl J Med (2009) 2.29
Cardiovascular death in kidney recipients treated with renin-angiotensin system blockers. Transplantation (2014) 1.96
H-Y as a minor histocompatibility antigen in kidney transplantation: a retrospective cohort study. Lancet (2008) 1.85
Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant (2005) 1.78
The effect of donor gender on graft survival. J Am Soc Nephrol (2002) 1.72
No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report. Transplantation (2011) 1.67
Pediatric kidney transplantation: analysis of donor age, HLA match, and posttransplant non-Hodgkin lymphoma: a collaborative transplant study report. Transplantation (2010) 1.60
Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. Lancet Oncol (2007) 1.51
Prolongation of long-term kidney graft survival by a simultaneous liver transplant: the liver does it, and the heart does it too. Transplantation (2002) 1.48
Impact of HLA compatibility on lung transplant survival and evidence for an HLA restriction phenomenon: a collaborative transplant study report. Transplantation (2010) 1.42
Kidney graft survival in Europe and the United States: strikingly different long-term outcomes. Transplantation (2013) 1.36
Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant (2005) 1.18
Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation (2006) 1.11
Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction: results from 101 centers. Transplantation (2015) 1.05
No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol (2006) 1.05
Influence of time of rejection on long-term graft survival in renal transplantation. Transplantation (2008) 1.04
Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades. Transplantation (2007) 1.03
Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation (2009) 1.02
Metabolic control improves long-term renal allograft and patient survival in type 1 diabetes. J Am Soc Nephrol (2008) 1.02
Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant (2004) 1.01
Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation (2008) 1.00
Inosine monophosphate dehydrogenase polymorphisms and renal allograft outcome. Transplantation (2012) 0.99
Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation (2009) 0.99
Donor ABCB1 variant associates with increased risk for kidney allograft failure. J Am Soc Nephrol (2012) 0.98
Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report. Hum Immunol (2009) 0.93
HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: a collaborative transplant study report. Transplantation (2009) 0.91
Impact of HLA mismatching on incidence of posttransplant non-hodgkin lymphoma after kidney transplantation. Transplantation (2010) 0.89
HLA matching and kidney transplantation: beyond graft survival. Clin Transpl (2013) 0.88
Genotypic diversity of complement component C4 does not predict kidney transplant outcome. J Am Soc Nephrol (2010) 0.86
Risks of allogeneic hand transplantation. Microsurgery (2004) 0.84
Increased pretransplantation plasma kynurenine levels do not protect from but predict acute kidney allograft rejection. Hum Immunol (2010) 0.83
Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing. Transplantation (2015) 0.82
The collaborative transplant study registry. Transplant Rev (Orlando) (2013) 0.81
Transplantation of the type 1 diabetic patient: the long-term benefit of a functioning pancreas allograft. Clin J Am Soc Nephrol (2010) 0.81
Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol (2002) 0.81
Analysis of positive kidney, heart, and liver transplant crossmatches reported to the Collaborative Transplant Study. Hum Immunol (2009) 0.81
VEGF 936 C/T gene polymorphism in renal transplant recipients: association of the T allele with good graft outcome. Hum Immunol (2007) 0.80
Soluble CD30 as a predictor of kidney graft outcome. Transplantation (2002) 0.79
Posttransplant sCD30 as a predictor of kidney graft outcome. Transplantation (2011) 0.79
Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma. Blood (2010) 0.79
Influence of Current and Previous Smoking on Cancer and Mortality After Kidney Transplantation. Transplantation (2016) 0.78
Association of mismatches for HLA-DR with incidence of posttransplant hip fracture in kidney transplant recipients. Transplantation (2011) 0.78
Deleterious impact of HLA-DRB1 allele mismatch in sensitized recipients of kidney retransplants. Transplantation (2013) 0.77
Deleterious impact of mismatching for human leukocyte antigen-C in presensitized recipients of kidney transplants. Transplantation (2011) 0.77
Reduced rate of cardiovascular death after cytomegalovirus prophylaxis in renal transplant recipients. Transplantation (2015) 0.77
Does borderline kidney allograft rejection always require treatment? Transplantation (2010) 0.76
The role of pretransplant dialysis modality on renal allograft outcome. Nephrol Dial Transplant (2011) 0.76
Renin-Angiotensin system blockers and cardiovascular death in kidney recipients. Transplantation (2014) 0.75
Response to A reassessment of the Survival Advantage of Simultaneous Kidney-Pancreas Versus Kidney-Alone Transplantation. Transplantation (2015) 0.75
HLA Matching in Pediatric Kidney Transplantation: HLA Poorly Matched Living Donor Transplants Versus HLA Well Matched Deceased Donor Transplants. Transplantation (2017) 0.75
High Posttransplant Cancer Incidence in Renal Transplanted Patients With Pretransplant Cancer. Transplantation (2017) 0.75
Genetic polymorphisms of adhesion molecules and kidney transplant survival. Transplantation (2010) 0.75
Association of pretransplant soluble glycoprotein 130 (sgp130) plasma levels and posttransplant acute tubular necrosis in renal transplant recipients. Transplantation (2009) 0.75
Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience. Nephrol Dial Transplant (2012) 0.75
Association of single nucleotide polymorphisms on chromosome 9p21.3 with cardiovascular death in kidney transplant recipients. Transplantation (2013) 0.75